RT Book, Section
A1 Heuser, Michael
A1 Thol, Felicitas
A2 Murray, Michael F.
A2 Babyatsky, Mark W.
A2 Giovanni, Monica A.
A2 Alkuraya, Fowzan S.
A2 Stewart, Douglas R.
SR Print(0)
ID 1102700048
T1 Acute Myeloid Leukemia
T2 Clinical Genomics: Practical Applications in Adult Patient Care
YR 2014
FD 2014
PB McGraw-Hill Education
PP New York, NY
SN 9780071622448
LK accessbiomedicalscience.mhmedical.com/content.aspx?aid=1102700048
RD 2024/04/18
AB Disease  summary:Acute  myeloid  leukemia  (AML)  is  a  malignant  disease  originating  from  a  hematopoietic  cell  that  has  acquired  self-renewal  properties.  Hundreds  of  genetic  aberrations  have  been  described  in  AML  cells,  and  recent  evidence  suggests  that  on  average  13  genetic  aberrations  are  present  in  AML  cells.Patients  usually  present  with  signs  of  anemia,  infection,  or  bleeding.The  diagnosis  is  made  if  greater  than  or  equal  to  20  myeloid  blasts  are  present  in  peripheral  blood  or  bone  marrow.Conventional  cytogenetics  and  molecular  screening  for  fusion  proteins  PML-RARα,  RUNX1-RUNX1T1,  CBFB-MYH11,  and  for  mutations  of  NPM1,  CEBPA,  and  FLT3  should  be  obtained  at  diagnosis.Intensive  chemotherapy  should  be  given  to  all  eligible  patients  consisting  of  cytarabine  and  an  anthracycline.Consolidation  treatment  consists  of  high-dose  cytarabine  or  allogeneic  hematopoietic  stem  cell  transplantation  depending  on  prognostic  factors.Acute  promyelocytic  leukemia  (APL)  is  treated  differently  than  other  AML  patients  (including  all-trans  retinoic  acid  [ATRA]  and  an  anthracycline)  and  has  a  good  prognosis.